National and Kapodistrian University of Athens
Μεταμόσχευση νεφρού με ασύμβατη ομάδα αίματος μεταξύ δότη και λήπτη
Abstract
dc:descriptionBACKGROUND: Despite intensive efforts to promote post-mortem organ donation, the transplant community persistently faces a worldwide shortage of kidney grafts. The profound donor shortage in renal transplantation has led to a reconsideration of the immunological barriers previously viewed as contraindications to transplantation. One such immunological barrier is ABO incompatibility between donor and recipient. ABO-incompatible kidney transplantation is a promising strategy for enlargement of living-donor pools. In recent years, recipient desensitization by blood group antigen-specific immunoadsorption, together with rituximab and intravenous immunoglobulin, has allowed excellent graft performance after ABO-incompatible transplantation. AIM: To be evaluated graft and patients survival, as well as complications following the first twenty seven (n=27) ABO-incompatible renal transplantations performed in Greece.MATERIALS & METHOD: Slightly modifying this protocol, originally described by Tyden and coworkers, we performed 27 living-donor renal transplants across the ABO barrier for the first time in Greece, between June 2005 and May 2011. We used a protocol of rituximab, antigen-specific immunoadsorption, intravenous immunoglobulin, daclizumab/basiliximab induction and oral triple immunosuppression with tacrolimus, everolimus/mycophenolate acid and methylprednisolone. The folowing parameters were closely monitored during the whole follow-up: graft function, proteinuria, blood group antibody titers, CMV and polyoma BK virus PCR in the blood, BK virus PCR in the urine and decoy cells. Protocol biopsies were performed at one year after transplantation as well as indication biopsies. RESULTS: After a median follow-up of 68 months (range 25-96), patient survival is 100% and graft survival is 92.6%. Mean serum creatinine is 1.7±0.5 mg/dl, mean eGFR is 64±15 ml/min/1.73m2 and mean 24h urine protein is 377±321 mg at the time of last follow-up. Three patients showed CMV viremia and one of them suffered CMV disease. All cases responded to treatment with valgancyclovir. Six patients had positive polyoma BK virus replication in the blood and urine and five of them developed polyoma virus-associated nephropathy (BKVAN). Three of the patients with BKVAN responded to treatment whereas two showed an inexorable decline of renal function. Acute humoral rejection type II was found in four patients. In two of them concominant acute cellular rejection Banff IIB was diagnosed. Isolated acute cellular rejection was observed in three patients, one of them showing borderline rejection and the other two, acute cellular rejection Banff IA. All rejection episodes resolved.CONCLUSION: ΑΒΟ incompatible renal transplantation seems to be successful and safe under a desensitization regimen consisting of rituximab and antigen-specific immunoadsorptions.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2014
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Theodoropoulou, Eleni
- Θεοδωροπούλου, Ελένη
Subjects
dc:subject × 16- Μεταμόσχευση νεφρού
- Ασύμβατη μεταμόσχευση
- Ομάδες αίματος
- Οξεία απόρριψη
- Χυμική απόρριψη
- Renal transplantation
- ABO-incompatible renal transplantation
- Blood groups
- Acute rejection
- Humoral rejection
- Ιατρική και Επιστήμες Υγείας
- Βασική Ιατρική
- Κλινική Ιατρική
- Medical and Health Sciences
- Basic Medicine
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/40967